Inhibikase Therapeutics Overview
Inhibikase Therapeutics Discounted Cash Flow
DCF Analysis for IKT.
Get informed when a big investor buys or sells
+ FollowFair Value
$1.42
Current Fair Value
$1.42
↓ 15.2% Downside
Overvalued by 15.2% based on the discounted cash flow analysis.
Average Upside/Downside (Comparison Companies)
Fair Value vs. Stock Price History
Upside/Downside History
Upside/Downside Comparison